Trial intelligence / Profile preview

Safety and sustainability of pain therapy with human adipose-derived mesenchymal stem cell conditioned medium

jRCT1050230167Recruiting

Sponsor
Suzuki Clinic Orthopaedics River City
Start
Aug 2023
Modality
Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Countries
1
01

Overview

Open-label, single-arm trial of human adipose-derived mesenchymal stem cell conditioned medium in chronic pain, sponsored by Suzuki Clinic Orthopaedics River City. Primary endpoints: Effect of pain on daily life, Pattern of pain and 3 more. Started Aug 2023; status: recruiting.

02

Drugs

human adipose-derived mesenchymal stem cell conditioned medium
03

Conditions

chronic pain

Beyond the preview

Go deeper on jRCT1050230167.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT1050230167.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call